ABSTRACT
Background The SARS-CoV-2 pandemic, with all its impacts on our way of life, is affecting our experiences and mental health. Notably, individuals with mental disorders have been reported to have a higher risk of contracting SARS-CoV-2. Personality traits could represent an important determinant of preventative health behavior and, therefore, the risk of contracting the virus.
Aims We examined overlapping genetic underpinnings between major psychiatric disorders, personality traits, and susceptibility to SARS-CoV-2 infection.
Methods Linkage disequilibrium score regression was used to explore the genetic correlations of COVID-19 susceptibility with psychiatric disorders and personality traits based on data from the largest available respective genome-wide association studies (GWAS). In two cohorts (the PsyCourse (n=1346) and the HeiDE (n=3266) study), polygenic risk scores were used to analyze if a genetic association between, psychiatric disorders, personality traits, and COVID-19 susceptibility exists in individual-level data.
Results We observed no significant genetic correlations of COVID-19 susceptibility with psychiatric disorders. For personality traits, there was a significant genetic correlation for COVID-19 susceptibility with extraversion (p=1.47×10-5; rg=0.284). Yet, this was not reflected in individual-level data from the PsyCourse and HeiDE studies.
Conclusions We identified no significant correlation between genetic risk factors for severe psychiatric disorders and genetic risk for COVID-19 susceptibility. Among the personality traits, extraversion showed evidence for a positive genetic association with COVID-19 susceptibility, in one but not in another setting. Overall, these findings highlight a complex contribution of genetic and non-genetic components in the interaction between COVID-19 susceptibility and personality traits or mental disorders.
Competing Interest Statement
MS is a member of the advisory board of Janssen. BTB reports the following COIs: Advisory Board of Lundbeck and Janssen-Cilag Consultant: National Health and Medical Research Council Australia Grant/Research Support: AstraZeneca, Fay Fuller Foundation, James & Diana Ramsay Foundation, National Health and Medical Research Council, Australia, German Research Council (DFG), Sanofi, Lundbeck, Honoraria: AstraZeneca, Bristol-Myers Squibb, Lundbeck, Pfizer, Servier Laboratories, Wyeth Pharmaceuticals, Takeda, Janssen, LivaNova PLC. OAA has received speaker honorarium from Lundbeck and Synovion, and is a consultant to HealthLytix. All other authors do not report conflicts of interest with regard to this manuscript.
Funding Statement
MMN is member of the DFG-funded Excellence Cluster ImmunoSensation2 (EXC 2151-390873048). This study was supported by ERA-NET NEURON grants EMBED (01EW1904 to MR), and SynSchiz: Linking synaptic dysfunction to disease mechanisms in schizophrenia: a multilevel investigation (01EW1810 to MR). TGS and PF are supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) within the framework of the projects www.kfo241.de and www.PsyCourse.de (SCHU 1603/4‐1, 5‐1, 7‐1; FA241/16‐1), ECS is also supported by the DFG (SCHU 2419/2-1) and through the Munich Clinician Scientist Program (MCSP). The genotyping was in part funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Program with grants awarded to TGS (01ZX1614K), MR (01ZX1614G), and MMN (01ZX1614A). TGS received additional support from the German Federal Ministry of Education and Research (BMBF) within the framework of the BipoLife network and the Dr. Lisa Oehler Foundation, Kassel (Germany). OAA received support from Research Council of Norway (#223273, #283798, #248980) and NordForsk (#105668).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures involving human subjects were approved by the Institutional Review Board at the University of Munich (13-17), the Institutional Review Board at the Medical Faculty of the University of Heidelberg (026/2001), or the local review boards of the primary studies that the utilized summary statistics were taken from(16, 19-22, 28).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵∇ shared senior authors
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos